KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand whom to position…
In the last decades, markedly improved survival benefit has been achieved in the treatment of advanced or metastatic HER2-positive breast cancer. Effective HER2-targeted drugs such as Herceptin,…
The treatment landscape of advanced platinum-sensitive ovarian cancer has been revolutionized by poly ADP ribose polymerase (PARP) inhibitors (AstraZeneca’s and Merck & Co.’s Lynparza, GSK’s…
The approvals of anti-PD-1/PD-L1 therapies—Keytruda (Merck & Co.), Opdivo (Bristol Myers Squibb), and Bavencio (Merck KGaA)—and antibody-drug conjugates—Padcev (Seagen / Astellas) and…
Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…